Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a contract research, development, and manufacturing organization (CRDMO). It provides integrated scientific services such as discovery, development, and manufacturing services. Syngene's proprietary platform, SynVent facilitates advancing programs through target validation, therapeutic discovery, translational interrogation, and pre-clinical development for biologics and small molecules. The company’s services cover chemistry, biology, safety assessment and toxicology, computational and data sciences, recombinant DNA engineering, cell line development, next-generation sequencing, hybridoma technology, and protein sciences. It serves pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. It operates in India and the US. Syngene is headquartered in Bangalore, Karnataka, India.
Headquarters
India
Address
Biocon Park, Sez, Bommasandra Industrial Area, Phase-IV, Jigani Link Road, Bengaluru, Karnataka, 560099
Website
www.syngeneintl.com
Telephone
91 80 68918000
No of Employees
6,533
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SYNGENE (NSE)
Revenue (2025)
$429.1M
4.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-2.7%
(2025 vs 2024)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
-6.8%
(2025 vs 2024)
* As of and is in US$
Syngene International Ltd premium industry data and analytics
Products and Services
| Services |
|---|
| Contract Research, Development, and Manufacturing Services |
| Formulation Development |
| Clinical Development |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, the company partnered with VivaMed BioPharma to integrate AI-generated drug repurposing hypotheses with Syngene’s preclinical validation and translational development infrastructure to accelerate therapeutic programs. |
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company, in a consortium with JSW Neo Energy and Goldman Sachs Services, acquired a 25.44% stake in O2 Power SPV O2 Renewable Energy V from Dalmia Cement (Bharat). |
| 2026 | Contracts/Agreements | In January, the company extended its research partnership with Bristol-Myers Squibb through 2035. |
Competitor Comparison
| Key Parameters | Syngene International Ltd | Pfizer Ltd India | Cohance Lifesciences Ltd | Sai Life Sciences Ltd | Hikal Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Bengaluru | Mumbai | Rangareddy | Hyderabad | Mumbai |
| State/Province | Karnataka | Maharashtra | Telangana | Telangana | Maharashtra |
| No. of Employees | 6,533 | 1,598 | 1,212 | 3,401 | 2,062 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kiran Mazumdar Shaw | Chairman | Executive Board | 2026 | - |
| Siddharth Mittal | Managing Director; Chief Executive Officer | Senior Management | 2026 | - |
| Deepak Jain | Chief Financial Officer | Senior Management | 2024 | - |
| Gaurav Kushwaha | Chief Technology Officer | Senior Management | 2025 | - |
| Jayashree Aiyar | Chief Scientific Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer